21.03.2022 • NewsSeqens

Seqens Invests in US R&D Laboratory

French API specialist Seqens is investing what it says is a multi-million-dollar sum in its US research and development laboratory at Devens, Massachusetts. The company said the improvements will increase its R&D capability and productivity in the US and strengthen its global network. Completion of the project is expected in October 2022.

The investment comes just three months after SK Capital acquired the majority of Seqens and merged it with its portfolio company Wavelength Pharmaceuticals to create a larger, highly diversified CDMO. Alongside SK, new investors Bpifrance and Nov Sante’ now flank existing shareholders Mérieux Equity Partners, Ardian and Eximium.

The merger with Wavelength extends Seqens’ global reach by adding production facilities in Israel and India and sales offices in Europe and the US. It also broadens the French company’s API portfolio and its cytotoxic, steroidal and high-potency products with the addition of Wavelength’s complementary expertise in complex pharmaceutical synthesis.

In total, the expanded portfolio now includes 200 active pharmaceutical ingredients (APIs), 500 pharmaceutical intermediates, as well as key specialty ingredients and chemicals.

In addition to the redevelopment of its Devens lab, Seqens said it is investing significantly across the enterprise to support its customers’ growth in both commercial and development products and technology platforms, including custom polymers, lipids, flow chemistry, high potency APIs and biocatalysts.

Author: Dede Williams, Freelance Journalist 

(c) Seqens
(c) Seqens

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
24.01.2025 • News

And the Winners are: Cynio, EnaDyne and Green Li-ion

The CHEManager Innovation Pitch, the start-up promotion initiative of CHEManager and CHEManager International, has given more than 100 start-ups from over 15 countries the opportunity to present their innovative ideas, products and technologies to a broad target group since its launch in 2019.

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.

Photo
08.11.2024 • News

Future Prospects in Green Chemistry

The Discourse on Green Chemistry Interactive Pitch Competition, held on November 5, 2024, at Wiley's Berlin office as part of Berlin Science Week, showcased a range of innovative projects aimed at addressing critical environmental challenges.